US2001014663A1PendingUtilityA1

Treatment of allograft rejection with anti-angiogenic agents

44
Priority: Nov 18, 1998Filed: Jan 17, 2001Published: Aug 16, 2001
Est. expiryNov 18, 2018(expired)· nominal 20-yr term from priority
Inventors:David M. BriscoeKaren MoultonMohamed H. Sayegh
A61K 31/336A61K 31/335A61K 38/13
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates a method of inhibiting allograft rejection in a subject with an organ transplant. The method comprises administering an effective amount of one or more anti-angiogenic agents to a subject alone or in combination with one or more immunosuppressive agents. The invention provides new and improved methods of inhibiting allograft rejection.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of inhibiting allograft rejection in a subject with an organ transplant comprising the step of administering an effective amount of one or more anti-angiogenic agents, with the proviso that the anti-angiogenic agent is not thalidomide.  
     
     
         2 . The method of    claim 1    wherein the subject is being treated for acute allograft rejection.  
     
     
         3 . The method of    claim 2    wherein the anti-angiogenic agent is endostatin.  
     
     
         4 . The method of    claim 2    wherein the anti-angiogenic agent is angiostatin.  
     
     
         5 . The method of    claim 2    wherein the anti-angiogenic agent is AGM 1470 or an analogue.  
     
     
         6 . The method of    claim 5    wherein the anti-angiogenic agent is TNP-470.  
     
     
         7 . The method of    claim 2    wherein the transplanted organ is a kidney or heart.  
     
     
         8 . The method of    claim 2    wherein the anti-angiogenic agent is co-administered with an effective amount of one or more immunosuppressive agents.  
     
     
         9 . The method of    claim 8    wherein the immunosuppressive agent is cyclosporine.  
     
     
         10 . The method of    claim 1    wherein the anti-angiogenic agent is a polypeptide.  
     
     
         11 . A method of inhibiting chronic allograft rejection in a subject with an organ transplant comprising the step of administering an effective amount of one or more anti-angiogenic agents.  
     
     
         12 . The method of    claim 11    wherein the anti-angiogenic agent is endostatin.  
     
     
         13 . The method of    claim 11    wherein the anti-angiogenic agent is angiostatin.  
     
     
         14 . The method of    claim 11    wherein the anti-angiogenic agent is AGM 1470 or an analogue.  
     
     
         15 . The method of    claim 14    wherein the anti-angiogenic agent is TNP-470.  
     
     
         16 . The method of    claim 11    wherein the transplanted organ is a kidney or heart.  
     
     
         17 . The method of    claim 11    wherein the anti-angiogenic agent is co-administered with an effective amount of one or more immunosuppressive agents.  
     
     
         18 . The method of    claim 17    wherein the immunosuppressive agent is cyclosporine.  
     
     
         19 . The method of    claim 11    wherein the anti-angiogenic agent is a polypeptide.

Join the waitlist — get patent alerts

Track US2001014663A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.